$7.23
11.75% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US52886X1072
Symbol
LXEO
Sector
Industry

Lexeo Therapeutics Stock price

$7.23
-2.27 23.89% 1M
-8.23 53.23% 6M
-6.19 46.13% YTD
-3.77 34.27% 1Y
-3.77 34.27% 3Y
-3.77 34.27% 5Y
-3.77 34.27% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.76 11.75%
ISIN
US52886X1072
Symbol
LXEO
Sector
Industry

Key metrics

Market capitalization $239.03m
Enterprise Value $92.41m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.72
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-93.36m
Free Cash Flow (TTM) Free Cash Flow $-67.37m
Cash position $157.02m
EPS (TTM) EPS $-2.84
P/E forward negative
Short interest 7.42%
Show more

Is Lexeo Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Lexeo Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Lexeo Therapeutics forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Lexeo Therapeutics forecast:

Buy
100%

Financial data from Lexeo Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.97 1.97
-
-
-1.97 -1.97
-
-
- Selling and Administrative Expenses 25 25
-
-
- Research and Development Expense 64 64
-
-
-91 -91
-
-
- Depreciation and Amortization 1.97 1.97
-
-
EBIT (Operating Income) EBIT -93 -93
-
-
Net Profit -87 -87
-
-

In millions USD.

Don't miss a Thing! We will send you all news about Lexeo Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexeo Therapeutics Stock News

Neutral
GlobeNewsWire
13 days ago
Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased int...
Neutral
GlobeNewsWire
27 days ago
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact Underlying Genetic Cause of APOE4-Associated Alzheimer's
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentatio...
More Lexeo Therapeutics News

Company Profile

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The firm focuses on the medication of genetically defined cardiovascular diseases and sub-group of Alzheimer’s disease. It offers LX2006 for the treatment of patients with Friedreich's ataxia, cardiomyopathy, and LX1001 for APOE4 homozygous patients with Alzheimer's disease. The company was founded by Ronald G. Crystal in February 2017 and is headquartered in New York, NY.

Head office United States
CEO R. Townsend
Employees 58
Founded 2017
Website www.lexeotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today